Announced Fri, 26 Jun · 18:12 IST
Board approves proposal to raise up to Rs 50 crore
Board & Shareholder Meetings View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.4%1-day move
₹39.75
prior close
₹39.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
—+4.5+3.1—-0.4+0.1+0.6+0.5-0.8-5.4-12.9———
Up moveDown movePending
AI summary
Bacil Pharma's Board, at its meeting on 26 June 2026, approved raising funds up to Rs 50 crore through permissible modes such as Rights Issue, Preferential Issue, convertible securities, or warrants. Mode, size, pricing and structure will be decided later based on market conditions. Board authorized MD, CFO and Company Secretary to evaluate options, appoint intermediaries and finalize terms. Subject to regulatory and shareholder approvals.
Likely market impact
Potential equity dilution for existing shareholders; specific terms not yet decided. Shareholder approval needed.